Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene therapy injection aims to halt blinding eye disease

NCT ID NCT07705568

Not yet recruiting Disease control Sponsor: Eyevensys Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This trial tests a gene therapy called PST-611 in people aged 65 and older with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. PST-611 is a DNA plasmid injected into the eye muscle that instructs cells to produce human transferrin, a protein that may protect the retina. Participants receive one injection every 20 weeks for three doses and are followed for a year to check safety and any changes in vision or retinal structure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a gene therapy called PST-611, a DNA plasmid that instructs cells to produce human transferrin, injected into the eye muscle
What this could lead to
If successful, PST-611 could slow or stop the progression of geographic atrophy, a leading cause of blindness in older adults, for which there are limited treatments.
What could go wrong
This is a small, early-phase trial focused on safety, so it is not designed to prove effectiveness. The treatment may not slow vision loss and could cause side effects like eye inflammation or increased pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION (AMD) GEOGRAPHIC ATROPHY GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Grenoble-Hôpital Michallon

    Grenoble, France, 38043, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hôpital Cochin

    Paris, France, 75014, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hôpital Lariboisière

    Paris, France, 75010, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.